Trial Profile
A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 May 2014
Price :
$35
*
At a glance
- Drugs 552 02 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Parion Sciences
- 13 May 2014 New trial record